RNA (Atrium Therapeutics) Pretax Margin %: -84.71% (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Pretax Margin %?

Atrium Therapeutics RNA +0.16% 12 Pretax Margin % is -84.71% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Atrium Therapeutics ranks worse than 65.05% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Atrium Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was $-16.63 Mil. Atrium Therapeutics's Revenue for the three months ended in Mar. 2026 was $19.64 Mil. Therefore, Atrium Therapeutics's pretax margin for the quarter that ended in Mar. 2026 was -84.71%.

The historical rank and industry rank for Atrium Therapeutics's Pretax Margin % or its related term are showing as below:

RNA' s Pretax Margin % Range Over the Past 10 Years
Min: -412.64   Med: -121.28   Max: -65.39
Current: -315.55

RNA's Pretax Margin % is ranked worse than
65.05% of 947 companies
in the Biotechnology industry
Industry Median: -92.22 vs RNA: -315.55

Atrium Therapeutics  (NAS:RNA) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Atrium Therapeutics Pretax Margin % Related Terms

Atrium Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Pretax Margin % Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Pretax Margin %
-65.39 -121.28 -412.64

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial -210.12 -473.55 0.00 -5,591.97 -84.71

RNA vs RNAC, KROS, ARCT: Pretax Margin % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's Pretax Margin % falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Atrium Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-76.826/18.618
=-412.64 %

Atrium Therapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.633/19.635
=-84.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -84.71% mean?
Atrium Therapeutics (RNA) has a Pretax Margin % of -84.71% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Atrium Therapeutics and its competitors. According to the industry distribution chart, Atrium Therapeutics ranks #616 out of 947 companies in the Biotechnology industry, placing it in the top 65%.
Is Atrium Therapeutics' Pretax Margin % too high?
Atrium Therapeutics' current Pretax Margin % is -84.71%. Based on the distribution chart, Atrium Therapeutics ranks #616 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Pretax Margin % compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #616 out of 947 companies for Pretax Margin %. This places Atrium Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Pretax Margin % is -84.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Pretax Margin % of -84.71%. The current Pretax Margin % is -84.71%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Pretax Margin % is -84.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price